✦ LIBER ✦

A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer

✍ Scribed by Liu, Joyce F.; Tolaney, Sara M.; Birrer, Michael; Fleming, Gini F.; Buss, Mary K.; Dahlberg, Suzanne E.; Lee, Hang; Whalen, Christin; Tyburski, Karin; Winer, Eric; Ivy, Percy; Matulonis, Ursula A.

Book ID: 120526798
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 580 KB
Volume: 49
Category: Article
ISSN: 0959-8049
DOI: 10.1016/j.ejca.2013.05.020

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Oral poly(ADP-ribose) polymerase inhibit

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

✍ M William Audeh; James Carmichael; Richard T Penson; Michael Friedlander; Bethan 📂 Article 📅 2010 🏛 The Lancet 🌐 English ⚖ 268 KB

G2 Efficacy of BSI-201, a poly (ADP-ribo

G2 Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): results of a randomized phase II trial

✍ J. O'Shaughnessy; C. Osborne; J. Pippen; M. Yoffe; D. Patt; G. Monaghan; C. Roch 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 49 KB

Phase II, Open-Label, Randomized, Multic

Phase II, Open-Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of Olaparib, a Poly (ADP-Ribose) Polymerase Inhibitor, and Pegylated Liposomal Doxorubicin in Patients With BRCA1 or BRCA2 Mutations and Recurrent Ovarian Cancer

✍ Kaye, S. B.; Lubinski, J.; Matulonis, U.; Ang, J. E.; Gourley, C.; Karlan, B. Y. 📂 Article 📅 2012 🏛 American Society of Clinical Oncology 🌐 English ⚖ 165 KB